-The Tribune BARC reports toxic metals in fertilisers as firms avoid costly decontamination process Bathinda (Punjab): The Bhabha Atomic Research Centre (BARC) has found high uranium content in diammonium phosphate and single superphosphate fertilisers that do not undergo the costlier decontamination process during production. The conclusion was reached after testing of soil and fertiliser samples. The Environmental Assessment Division of BARC sent a report on samples of DAP (diammonium phosphate) and single superphosphate...

-The Hindu It is not the responsibility of the government alone to act in order to curb corruption; corporate firms need to be proactive as well in checking fraudulent financial practices The winter session of Parliament witnessed a noisy debate on the black money controversy. Governments of all hues have disappointed the Indian janata on the issue of black money and the failure is often associated with a perceived nexus between politicians...

-Business Standard Domestic regulators need to be stricter about quality violations to protect both Indian pharma exports as well as the country's image Even as major Indian drug companies continue to make news for impurities in the medicines they make and faulty - or if the USFDA is to be believed, falsified - data that many generate after testing of samples show quality problem, it seems strange that domestic authorities are silent...

-The Telegraph Regulators in several European countries are suspending marketing approval for 25 generic drugs because of concerns over the quality of data from human studies conducted by an Indian contract research company, a French medical safety agency said on Friday. Drug regulators in Belgium, France, Germany and Luxembourg have decided to suspend the marketing authorisation for the generic drugs after they discovered "irregularities" in documents relating to human studies conducted by...

-The Times of India NEW DELHI: The drug price regulator has mandated companies to seek its approval for every new medicine, including combinations of existing ones, to ensure that consumers are not overcharged. According to the National Pharmaceutical Pricing Authority (NPPA) all innovative launches like new combinations of price-controlled medicines as well as those with changed strengths and dosages will be treated as 'new medicines'. The move is aimed at spanning the...